MP74-03 LOW FREE AND BIOAVAILABLE TESTOSTERONE LEVELS CAN PREDICT HIGH-GRADE PROSTATE CANCER: PROSPECTIVE, CLINICAL STUDY

Abstract

You have accessJournal of UrologyProstate Cancer: Markers I1 Apr 2014MP74-03 LOW FREE AND BIOAVAILABLE TESTOSTERONE LEVELS CAN PREDICT HIGH-GRADE PROSTATE CANCER: PROSPECTIVE, CLINICAL STUDY Goksel Bayar, Mustafa Kadihasanoglu, Mustafa Aydin, Umut Sariogullari, Orhan Tanriverdi, and Muammer Kendirci Goksel BayarGoksel Bayar More articles by this author , Mustafa KadihasanogluMustafa Kadihasanoglu More articles by this author , Mustafa AydinMustafa Aydin More articles by this author , Umut SariogullariUmut Sariogullari More articles by this author , Orhan TanriverdiOrhan Tanriverdi More articles by this author , and Muammer KendirciMuammer Kendirci More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.2336AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To evaluate the predictive value of blood free and bioavailable levels on the detection of high-grade prostate cancer proven by transrectal prostate biopsy. METHODS A total of 344 patients who underwent transrectal prostate biopsy due to high PSA levels of >2.5 ng/ml or abnormal findings at digital rectal exam were included into this study. Those patients who had been on testosterone replacement or 5-ARI therapies were excluded. Blood samples were taken between 07-10 o’clock for measuring blood total testosterone, PSA, SHBG and albumin levels. The free and bioavailable testosterone levels were calculated by the formula provided by ISSAM. Patients were stratified according to the D’Amico classification by PSA levels and histological outcomes of prostate biopsies as benign, low- medium risk and high-grade prostate cancer. Patients were also divided into five groups according to cancerous biopsy core rate. Mann-Whitney-U and Kruskal-Wallis tests were used for statistical analysis, and p<0.05 was considered as significant. RESULTS Prostate cancer was detected in 155 of 344 (45%) patients. Blood total, free and bioavailable testosterone levels were unable to differentiate benign and malign histology. However, blood free (6.2 vs. 5.2 ng/dl, p= 0.002) and bioavailable testosterone levels (151 vs. 125 ng/dl p= 0.001) were found to be significantly different in men with low-medium and high-risk prostate cancer patients (Table). A correlation could not be found between free and bioavailable testosterone levels and rates of cores with cancer (p= 0.332) (Figure). CONCLUSIONS This study demonstrated that reduced levels of calculated blood free and bioavailable testosterone are associated with an increased risk of high-grade prostate biopsy. We think that blood free and bioavailable testosterone levels can be used to predict high-risk prostate cancer. Low-medium risk prostate cancer High-grade prostate cancer p value Patients no. (n) 96 59 Total Testosterone (ng/dL) 356±132 327±121 0.174 Albumin (g/dL) 4.4±0.3 4.3±0.4 0.161 SHBG (nmol/L) 39.4±14 45.9±18 0.086 Free Testosterone (ng/dL) 6.2±1.9 5.2±1.6 0.002* Bioavailable Testosterone (ng/dL) 151±47 125±43 0.001* © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e856-e857 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Goksel Bayar More articles by this author Mustafa Kadihasanoglu More articles by this author Mustafa Aydin More articles by this author Umut Sariogullari More articles by this author Orhan Tanriverdi More articles by this author Muammer Kendirci More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...